Myricetin alleviates diabetic cardiomyopathy by regulating gut microbiota and their metabolites.

IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Jinxiu Zhu, Zhijun Bao, Zuoqi Hu, Shenglin Wu, Cuihong Tian, Yueran Zhou, Zipeng Ding, Xuerui Tan
{"title":"Myricetin alleviates diabetic cardiomyopathy by regulating gut microbiota and their metabolites.","authors":"Jinxiu Zhu, Zhijun Bao, Zuoqi Hu, Shenglin Wu, Cuihong Tian, Yueran Zhou, Zipeng Ding, Xuerui Tan","doi":"10.1038/s41387-024-00268-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The gut microbiota is involved in the pathogenesis of diabetic cardiomyopathy (DCM). Myricetin protects cardiac function in DCM. However, the low bioavailability of myricetin fails to explain its pharmacological mechanisms thoroughly. Research has shown that myricetin has a positive effect on the gut microbiota. We hypothesize that myricetin improves the development of DCM via regulating gut microbiota.</p><p><strong>Methods: </strong>DCM mice were induced with streptozotocin and fed a high-fat diet, and then treated with myricetin by gavage and high-fat diet for 16 weeks. Indexes related to gut microbiota composition, cardiac structure, cardiac function, intestinal barrier function, and inflammation were detected. Moreover, the gut contents were transplanted to DCM mice, and the effect of fecal microbiota transplantation (FMT) on DCM mice was assessed.</p><p><strong>Results: </strong>Myricetin could improve cardiac function in DCM mice by decreasing cardiomyocyte hypertrophy and interstitial fibrosis. The composition of gut microbiota, especially for short-chain fatty acid-producing bacteria involving Roseburia, Faecalibaculum, and Bifidobacterium, was more abundant by myricetin treatment in DCM mice. Myricetin increased occludin expression and the number of goblet cells in DCM mice. Compared with DCM mice unfed with gut content, the cardiac function, number of goblet cells, and expression of occludin in DCM mice fed by gut contents were elevated, while cardiomyocyte hypertrophy and TLR4/MyD88 pathway-related proteins were decreased.</p><p><strong>Conclusions: </strong>Myricetin can prevent DCM development by increasing the abundance of beneficial gut microbiota and restoring the gut barrier function.</p>","PeriodicalId":19339,"journal":{"name":"Nutrition & Diabetes","volume":"14 1","pages":"10"},"PeriodicalIF":4.6000,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10933338/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition & Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41387-024-00268-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The gut microbiota is involved in the pathogenesis of diabetic cardiomyopathy (DCM). Myricetin protects cardiac function in DCM. However, the low bioavailability of myricetin fails to explain its pharmacological mechanisms thoroughly. Research has shown that myricetin has a positive effect on the gut microbiota. We hypothesize that myricetin improves the development of DCM via regulating gut microbiota.

Methods: DCM mice were induced with streptozotocin and fed a high-fat diet, and then treated with myricetin by gavage and high-fat diet for 16 weeks. Indexes related to gut microbiota composition, cardiac structure, cardiac function, intestinal barrier function, and inflammation were detected. Moreover, the gut contents were transplanted to DCM mice, and the effect of fecal microbiota transplantation (FMT) on DCM mice was assessed.

Results: Myricetin could improve cardiac function in DCM mice by decreasing cardiomyocyte hypertrophy and interstitial fibrosis. The composition of gut microbiota, especially for short-chain fatty acid-producing bacteria involving Roseburia, Faecalibaculum, and Bifidobacterium, was more abundant by myricetin treatment in DCM mice. Myricetin increased occludin expression and the number of goblet cells in DCM mice. Compared with DCM mice unfed with gut content, the cardiac function, number of goblet cells, and expression of occludin in DCM mice fed by gut contents were elevated, while cardiomyocyte hypertrophy and TLR4/MyD88 pathway-related proteins were decreased.

Conclusions: Myricetin can prevent DCM development by increasing the abundance of beneficial gut microbiota and restoring the gut barrier function.

Abstract Image

杨梅素通过调节肠道微生物群及其代谢产物缓解糖尿病心肌病。
背景:肠道微生物群与糖尿病心肌病(DCM)的发病机制有关。杨梅素能保护 DCM 患者的心脏功能。然而,由于没食子酸的生物利用度较低,因此无法彻底解释其药理机制。研究表明,杨梅素对肠道微生物群有积极影响。我们假设,杨梅素通过调节肠道微生物群来改善 DCM 的发展:方法:用链脲佐菌素诱导 DCM 小鼠并喂食高脂饮食,然后通过灌胃和喂食高脂饮食的方式用杨梅素治疗 DCM 小鼠 16 周。检测了与肠道微生物群组成、心脏结构、心脏功能、肠道屏障功能和炎症相关的指标。此外,还将肠道内容物移植到DCM小鼠体内,评估粪便微生物群移植(FMT)对DCM小鼠的影响:结果:米曲汀能通过减少心肌细胞肥大和间质纤维化改善DCM小鼠的心脏功能。DCM小鼠肠道微生物群的组成,尤其是Roseburia、Faecalibaculum和Bifidobacterium等产短链脂肪酸的细菌的组成,在三叶草素治疗后更为丰富。三尖杉酯素增加了 DCM 小鼠的闭塞素表达和鹅口疮细胞数量。与未喂食肠道内容物的DCM小鼠相比,喂食肠道内容物的DCM小鼠的心脏功能、鹅口疮细胞数量和闭塞素的表达均升高,而心肌细胞肥大和TLR4/MyD88通路相关蛋白则降低:结论:杨梅素可以通过增加有益肠道微生物群的丰度和恢复肠道屏障功能来预防 DCM 的发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nutrition & Diabetes
Nutrition & Diabetes ENDOCRINOLOGY & METABOLISM-NUTRITION & DIETETICS
CiteScore
9.20
自引率
0.00%
发文量
50
审稿时长
>12 weeks
期刊介绍: Nutrition & Diabetes is a peer-reviewed, online, open access journal bringing to the fore outstanding research in the areas of nutrition and chronic disease, including diabetes, from the molecular to the population level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信